Get the Stockscreener App
18.06
2.79%
0.49
After Hours:
18.12
0.06
+0.33%
Mediwound Ltd stock is traded at $18.06, with a volume of 38,759.
It is up +2.79% in the last 24 hours and down -1.79% over the past month.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
See More
Previous Close:
$17.57
Open:
$17.49
24h Volume:
38,759
Relative Volume:
0.24
Market Cap:
$192.97M
Revenue:
$19.85M
Net Income/Loss:
$-12.75M
P/E Ratio:
-7.4321
EPS:
-2.43
Net Cash Flow:
$-21.94M
1W Performance:
+3.08%
1M Performance:
-1.79%
6M Performance:
+26.74%
1Y Performance:
+69.74%
1-Day Range:
$17.44
$18.12
1-Week Range:
$16.66
$18.12
52-Week Range:
$7.45
$24.00
Mediwound Ltd Stock (MDWD) Company Profile
Mediwound Ltd Stock (MDWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-22 | Initiated | Maxim Group | Buy |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Sep-23-20 | Initiated | BTIG Research | Buy |
| Nov-28-16 | Initiated | Aegis Capital | Buy |
| Aug-17-16 | Initiated | Wells Fargo | Outperform |
| Apr-16-14 | Initiated | Oppenheimer | Outperform |
View All
Mediwound Ltd Stock (MDWD) Latest News
Rhumbline Advisers Purchases Shares of 8,440 MediWound Ltd. (NASDAQ:MDWD) - Defense World
Objective long/short (MDWD) Report - Stock Traders Daily
TD Cowen maintains Buy rating on MediWound shares with no price target change - Investing.com
TD Cowen maintains Buy rating on MediWound shares with no price target change - Investing.com Canada
TD Cowen maintains Buy rating on MediWound shares with no price target change - Investing.com India
MediWound (NASDAQ:MDWD) Stock Price Crosses Below 200-Day Moving Average of $16.99 - MarketBeat
(MDWD) Long Term Investment Analysis - Stock Traders Daily
MediWound (NASDAQ:MDWD) Shares Cross Above 50 Day Moving Average of $18.20 - MarketBeat
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
MediWound (NASDAQ:MDWD) Shares Cross Above 50 Day Moving Average of $18.20 - Defense World
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Critical Comparison: MediWound (NASDAQ:MDWD) versus Jinhua Marine Biological (OTCMKTS:JNMB) - Defense World
MediWound Ltd.'s (NASDAQ:MDWD) top owners are retail investors with 38% stake, while 28% is held by institutions - Yahoo Finance
MDWDMediWound Ltd. Latest Stock News & Market Updates - StockTitan
MediWound Ltd. Forecasted to Post Q3 2024 Earnings of ($0.49) Per Share (NASDAQ:MDWD) - MarketBeat
Brokers Set Expectations for MediWound Ltd.’s Q3 2024 Earnings (NASDAQ:MDWD) - Defense World
MediWound (FRA:M8W) Median PS Value : €30.03 (As of Aug. 24, 2024) - GuruFocus.com
MDWD (MediWound) Free Cash Flow : $-22.27 Mil (TTM As of Jun. 2024) - GuruFocus.com
HC Wainwright Reiterates Buy Rating for MediWound (NASDAQ:MDWD) - Defense World
MediWound Ltd. (NASDAQ:MDWD) Forecasted to Earn FY2027 Earnings of $1.28 Per Share - Defense World
Equities Analysts Offer Predictions for MediWound Ltd.'s FY2027 Earnings (NASDAQ:MDWD) - MarketBeat
MediWound and Vericel win FDA paediatric label expansion for NexoBrid - Medical Device Network
MediWound and Vericel win FDA paediatric label expansion for NexoBrid - Yahoo Finance
MediWound shares hold Buy rating with steady target on expansion By Investing.com - Investing.com Australia
MediWound Second Quarter 2024 Earnings: EPS Misses Expectations - Simply Wall St
MediWound Announces U.S. Food and Drug Administration - GlobeNewswire
Vericel, MediWound climb on FDA's expanded approval for skin treatment - XM
MediWound’s NexoBrid Gains FDA Pediatric Approval - TipRanks
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns - StockTitan
MediWound shares hold Buy rating with steady target on expansion - Investing.com
MediWound shares hold Buy rating with steady target on expansion By Investing.com - Investing.com Canada
MediWound shares hold Buy rating with steady target on expansion By Investing.com - Investing.com UK
MediWound (NASDAQ:MDWD) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
MediWound: Q2 Earnings Snapshot - Darien Times
Earnings call: MediWound reports robust Q2 results, expands NexoBrid reach By Investing.com - Investing.com Australia
MediWound Ltd (MDWD) Q2 2024 Earnings Call Transcript Highlights: Revenue Growth Amidst Increased Losses - GuruFocus.com
Earnings call: MediWound reports robust Q2 results, expands NexoBrid reach By Investing.com - Investing.com India
Earnings call: MediWound reports robust Q2 results, expands NexoBrid reach - Investing.com India
Earnings call: MediWound reports robust Q2 results, expands NexoBrid reach By Investing.com - Investing.com UK
Earnings call: MediWound reports robust Q2 results, expands NexoBrid reach - Investing.com
MediWound: Q2 Earnings Snapshot - The Washington Post
MediWound: Q2 Earnings Snapshot - San Francisco Chronicle
Q2 2024 Mediwound Ltd Earnings Call Transcript - GuruFocus.com
MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
MediWound: Q2 Earnings Snapshot - Thehour.com
MediWound’s Strategic Growth and Solid Q2 2024 Performance - TipRanks
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - GlobeNewswire
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - wallstreet:online
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - Yahoo Finance
MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Mediwound Ltd Stock (MDWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):